Abstract
Targeting groups with the greatest burdens of cervical cancer is of public health importance as people now officially enter the era of human papillomavirus (HPV) vaccination. Two FDA-approved vaccines, Gardasil and Cervarix, are now available to prevent cervical cancer. Here, Chase and Tewari trace the trials leading to the approval of each vaccine, their indicated use, and future directions and considerations. The benefit of vaccination could include decreasing the number of abnormal Pap test results needing to be triaged, as well as reducing the number of invasive procedures for CIN.